| Literature DB >> 25330386 |
Cheng Hong Toh1, Kuo-Chen Wei2, Chen-Nen Chang2, Shu-Hang Ng3, Ho-Fai Wong3, Ching-Po Lin4.
Abstract
PURPOSE: To compare the diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MRI before and after mathematic contrast leakage correction in differentiating pyogenic brain abscesses from glioblastomas and/or metastatic brain tumors.Entities:
Mesh:
Year: 2014 PMID: 25330386 PMCID: PMC4201450 DOI: 10.1371/journal.pone.0109172
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Measurements of perfusion parameters in a 47-year-old man with pyogenic brain abscess.
Axial contrast-enhanced MPRAGE (A) and T2W image (B) show a rim-enhancing mass with perifocal edema in the right temporal lobe. (C) On contrast-enhanced MPRAGE, three ROIs are placed over the enhancing rim (red), perifocal edema (blue) most adjacent to the enhancing rim and the contralateral NAWM (green) for the measurements of CBV (D), corrected CBV (E) and K2 (F), respectively.
Figure 2MR perfusion of a glioblastoma and a metastatic brain tumor.
The upper panel shows the contrast-enhanced MPRAGE (A), CBV (B), corrected CBV (C) and K2 (D) images of a necrotic glioblastoma in the left medial parietal region, and the lower panel (E, F, G and H) shows the corresponding images of a cystic metastatic brain tumor in the right occipital lobe.
Quantitative comparisons of perfusion parameters among abscesses, glioblastomas and metastases.
| Region | Parameter | Abscess | GB | Mets | Abscess vs. GB | Abscess vs. Mets | GB vs. Mets |
| Enhancing rim | K2 | 1.33±1.29 | 0.92±0.79 | 1.22±1.45 | 0.508 | 0.968 | 0.706 |
| CBV | 1.45±1.17 | 3.85±2.19 | 2.39±0.90 | 0.001* | 0.030* | 0.034* | |
| Corrected CBV | 1.97±1.01 | 4.39±2.33 | 2.97±0.78 | 0.001* | 0.007* | 0.048* | |
| Perifocal edema | K2 | 0.28±0.27 | 0.14±0.16 | 0.11±0.10 | 0.198 | 0.072 | 0.786 |
| CBV | 1.04±0.43 | 1.54±1.21 | 0.88±0.33 | 0.242 | 0.432 | 0.082 | |
| Corrected CBV | 1.21±0.40 | 1.62±1.24 | 0.90±0.35 | 0.380 | 0.053 | 0.063 |
Note. – Data are mean ± standard deviation; CBV and corrected CBV are in ratios to corresponding NAWM, GB, glioblastomas; Mets, metastasis; *p<0.05.
ROC analysis of CBV and corrected CBV of enhancing rim in differentiating abscesses from glioblastomas and/or metastases.
| Group | Parameter | AUC | 95% CI | P value | CV | SEN | SPE | ACC |
| Abscess vs. GB | CBV | 0.839 | 0.712–0.966 | 0.001* | 2.17 | 78.9 | 76.5 | 77.8 |
| Corrected CBV | 0.851 | 0.729–0.974 | <.001* | 2.75 | 73.7 | 82.4 | 77.8 | |
| Abscess vs. Mets | CBV | 0.747 | 0.580–0.915 | 0.010* | 1.53 | 90.0 | 58.8 | 75.7 |
| Corrected CBV | 0.794 | 0.639–0.949 | 0.002* | 2.05 | 90.0 | 70.6 | 81.1 | |
| Abscess vs. GB & Mets | CBV | 0.792 | 0.658–0.925 | 0.001* | 1.51 | 89.7 | 58.8 | 80.4 |
| Corrected CBV | 0.822 | 0.700–0.944 | <.001* | 2.05 | 87.2 | 70.6 | 82.1 |
Note. – ACC, accuracy; CI, confidence interval; CV, cutoff value; GB, glioblastomas; Mets, metastasis; SEN, sensitivity; SPE, specificity; Data of sensitivity, specificity and accuracy are in percentage; *p<0.05.
Figure 3ROC curve analysis of CBV and corrected CBV in differentiating abscesses from glioblastomas (A), abscesses from metastases (B), and abscesses from glioblastomas and metastases.